Last 12 months
Inside the activity.
1 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 13, 2023 Filed Nov 15, 2023 21:41 UTC |
Kalayoglu MuratDirector · 10% owner
|
GrantCommon Stock | 257,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020921 · form4.xml · nonDerivative · entry 1 Kalayoglu Murat · CIK 0002000002 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,739 F1 · price: On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:40 UTC |
Miljkovic MilosChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 2,565.872 | Not disclosed Strike: $107.59 | Not disclosed |
DisclosureSEC source: 0001062993-23-020920 · form4.xml · derivative · entry 1 Miljkovic Milos · CIK 0002000282 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,565.872 Underlying: Series A Non-Voting Convertible Preferred Stock · 2,565.872 shares Expires 2031-09-12 F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition. F1 · derivative.exercise_date: Option is currently exercisable for 1,282.936 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and becomes exercisable for the remaining shares in two equal tranches on September 13, 2024 and 2025. F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 18:01 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 2,932 | $1.06 | $3,107.92 |
DisclosureSEC source: 0001453687-23-000068 · wk-form4_1695765647.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 783,081 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| September 25, 2023 Filed Sep 26, 2023 22:00 UTC |
TRABER PETER GChief Medical Officer
|
SaleCommon Stock | 705 | $1.06 | $747.30 |
DisclosureSEC source: 0001453687-23-000067 · wk-form4_1695765617.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,826 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · balance_after: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2022 and February 28, 2023. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:27 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
GiftCommon Stock | 26,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 4 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,316 F2 · kind: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 20:27 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
GiftCommon Stock | 26,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 3 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,816 F1 · kind: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 20:27 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
GiftCommon Stock | 43,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,316 F2 · kind: These transactions represent bona fide gifts from the Reporting Person to another adult child for which no consideration was paid. Read SEC document |
| May 30, 2023 Filed Jun 1, 2023 20:27 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
GiftCommon Stock | 43,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000054 · wk-form4_1685651220.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,316 F1 · kind: These transactions represent bona fide gifts from the Reporting Person to an adult child for which no consideration was paid. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 17:16 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 77 | $1.12 | $85.86 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 4 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,013 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 17:16 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 13,396 | $1.13 | $15,128.10 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 786,090 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:16 UTC |
Johnston Lloyd P.Chief Operations Officer
|
SaleCommon Stock | 20 | $1.11 | $22.21 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 4 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,515 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:16 UTC |
Johnston Lloyd P.Chief Operations Officer
|
SaleCommon Stock | 3,372 | $1.13 | $3,808.00 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 3 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,535 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
SaleCommon Stock | 20 | $1.11 | $22.23 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 4 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,316 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
SaleCommon Stock | 3,372 | $1.13 | $3,808.00 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 3 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,336 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC |
TRABER PETER GChief Medical Officer
|
SaleCommon Stock | 20 | $1.11 | $22.23 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 4 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,121 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 22:15 UTC |
TRABER PETER GChief Medical Officer
|
SaleCommon Stock | 3,445 | $1.13 | $3,890.44 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 3 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,141 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 17:16 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 48 | $1.15 | $54.96 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,486 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 17:16 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 27,549 | $1.13 | $31,232.30 |
DisclosureSEC source: 0001453687-23-000035 · wf-form4_167304337502065.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 799,534 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:16 UTC |
Johnston Lloyd P.Chief Operations Officer
|
SaleCommon Stock | 11 | $1.14 | $12.54 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,907 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:16 UTC |
Johnston Lloyd P.Chief Operations Officer
|
SaleCommon Stock | 6,381 | $1.13 | $7,234.14 |
DisclosureSEC source: 0001453687-23-000034 · wf-form4_167304335444381.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,918 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
SaleCommon Stock | 11 | $1.15 | $12.60 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,708 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
SaleCommon Stock | 6,381 | $1.13 | $7,234.14 |
DisclosureSEC source: 0001453687-23-000033 · wf-form4_167304333252079.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,719 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC |
TRABER PETER GChief Medical Officer
|
SaleCommon Stock | 15 | $1.14 | $17.13 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,586 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 22:15 UTC |
TRABER PETER GChief Medical Officer
|
SaleCommon Stock | 8,164 | $1.13 | $9,255.53 |
DisclosureSEC source: 0001453687-23-000032 · wf-form4_167304330841657.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,601 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:59 UTC |
SPRINGER TIMOTHY ADirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000016 · wf-form4_167286954984675.xml · derivative · entry 1 SPRINGER TIMOTHY A · CIK 0001055624 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:04 UTC |
ANDO GORANDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000024 · wf-form4_167286986208199.xml · derivative · entry 1 ANDO GORAN · CIK 0001110748 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:03 UTC |
COX CARRIE SMITHDirector
|
GrantStock Option (Right to Buy) · Derivative | 107,500 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000021 · wf-form4_167286975633037.xml · derivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,500 Underlying: Common Stock · 107,500 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 16:58 UTC |
ZENNER PATRICK JDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000014 · wf-form4_167286944573354.xml · derivative · entry 1 ZENNER PATRICK J · CIK 0001139036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:03 UTC |
Brunn CarstenDirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 1,275,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000022 · wf-form4_167286979042642.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,275,000 Underlying: Common Stock · 1,275,000 shares Expires 2033-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:03 UTC |
Brunn CarstenDirector · President and CEO
|
GrantCommon Stock | 282,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000022 · wf-form4_167286979042642.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,083 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 17:02 UTC |
DeSilva Nishan MDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000020 · wf-form4_167286972909668.xml · derivative · entry 1 DeSilva Nishan M · CIK 0001492386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:06 UTC |
Myers Scott DunsethDirector
|
GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000025 · wf-form4_167286995410639.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:04 UTC |
BARABE TIMOTHY CDirector
|
GrantStock Option (Right to Buy) · Derivative | 87,500 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000023 · wf-form4_167286983312515.xml · derivative · entry 1 BARABE TIMOTHY C · CIK 0001237409 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC |
Johnston Lloyd P.Chief Operations Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000019 · wf-form4_167286967765220.xml · derivative · entry 2 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2033-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC |
Johnston Lloyd P.Chief Operations Officer
|
GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000019 · wf-form4_167286967765220.xml · nonDerivative · entry 1 Johnston Lloyd P. · CIK 0001676905 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,299 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 475,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000018 · wf-form4_167286962791883.xml · derivative · entry 2 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2033-01-01 F3 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:01 UTC |
Kishimoto Takashi KeiChief Scientific Officer
|
GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000018 · wf-form4_167286962791883.xml · nonDerivative · entry 1 Kishimoto Takashi Kei · CIK 0001676930 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,100 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. F2 · balance_after: Includes 5,747 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2021 and February 28, 2022. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 22:00 UTC |
Sallin AymericDirector
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000017 · wf-form4_167286958364872.xml · derivative · entry 1 Sallin Aymeric · CIK 0001677660 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: The shares of Common Stock underlying this award will vest in full on January 2, 2024. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:59 UTC |
TRABER PETER GChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001453687-23-000015 · wf-form4_167286949656390.xml · derivative · entry 2 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2033-01-01 F3 · derivative.exercise_date: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2023 Filed Jan 4, 2023 21:59 UTC |
TRABER PETER GChief Medical Officer
|
GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-23-000015 · wf-form4_167286949656390.xml · nonDerivative · entry 1 TRABER PETER G · CIK 0001284500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,765 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027. F2 · balance_after: Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between March 1, 2022 and August 31, 2022. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 16:17 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 4,522 | $1.33 | $6,014.26 |
DisclosureSEC source: 0001453687-22-000147 · wf-form4_167044782270489.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,283 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:24 UTC |
Brunn CarstenDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000145 · wf-form4_167027547181099.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: This restricted stock unit award is fully vested and has no expiration date F2 · derivative.expiration_date: This restricted stock unit award is fully vested and has no expiration date Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 16:24 UTC |
Brunn CarstenDirector · President and CEO
|
Exercise / conversionCommon Stock | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000145 · wf-form4_167027547181099.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:40 UTC |
Davis BlaineChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001453687-22-000143 · wf-form4_166984440599363.xml · derivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2032-11-27 F1 · derivative.exercise_date: This option vests as to 25% on November 28, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 19:37 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 2,692 | $1.66 | $4,470.07 |
DisclosureSEC source: 0001453687-22-000131 · wf-form4_166458101110775.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 537,867 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.6604 to $1.6605. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:37 UTC |
Brunn CarstenDirector · President and CEO
|
SaleCommon Stock | 4,768 | $1.85 | $8,810.31 |
DisclosureSEC source: 0001453687-22-000129 · wf-form4_166251104851877.xml · nonDerivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,559 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $1.825 to $1.855. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:37 UTC |
Brunn CarstenDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000129 · wf-form4_166251104851877.xml · derivative · entry 3 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,938 Underlying: Common Stock · 10,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F4 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F4 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:37 UTC |
Brunn CarstenDirector · President and CEO
|
Exercise / conversionCommon Stock | 10,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000129 · wf-form4_166251104851877.xml · nonDerivative · entry 1 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:16 UTC |
COX CARRIE SMITHDirector
|
PurchaseCommon Stock | 130,000 | $1.15 | $149,799.00 |
DisclosureSEC source: 0001453687-22-000104 · wf-form4_165532415494758.xml · nonDerivative · entry 1 COX CARRIE SMITH · CIK 0001110753 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,881 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $1.13 to $1.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:44 UTC |
Brunn CarstenDirector · President and CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 10,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-22-000099 · wf-form4_165428903107199.xml · derivative · entry 2 Brunn Carsten · CIK 0001760229 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 Underlying: Common Stock · 10,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. F2 · derivative.expiration_date: This restricted stock unit vested as to 25% on December 1, 2019 and has vested, and will continue to vest, as to an additional 8.33% each quarter thereafter until fully vested. The restricted stock units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.